Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
COMBIVENT vs ALA-CORT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combivent is a fixed-dose combination of ipratropium bromide, an anticholinergic agent that inhibits muscarinic receptors in bronchial smooth muscle leading to bronchodilation, and albuterol sulfate, a beta-2 adrenergic agonist that stimulates adenyl cyclase, increasing cyclic AMP, resulting in bronchodilation.
Topical corticosteroid that induces phospholipase A2 inhibitory proteins, collectively called lipocortins, which inhibit the release of arachidonic acid, thereby reducing prostaglandin and leukotriene synthesis, and exerting anti-inflammatory, antipruritic, and vasoconstrictive effects.
Treatment of chronic obstructive pulmonary disease (COPD) exacerbations,Acute asthma exacerbations (off-label)
Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (FDA),Off-label: Atopic dermatitis, psoriasis, contact dermatitis, lichen planus, discoid lupus erythematosus
2 inhalations (ipratropium 18 mcg and albuterol 103 mcg per actuation) via oral inhalation 4 times daily; maximum 12 inhalations in 24 hours.
Topical: Apply a thin film to affected area 3-4 times daily. Dosage strength: 0.5% cream or ointment.
Ipratropium: terminal elimination half-life of approximately 2 hours (range 1.5-4 hours) after inhalation. Albuterol: terminal elimination half-life of approximately 3.8-6 hours after inhalation; systemic half-life is clinically relevant for dosing frequency in asthma/COPD.
Terminal elimination half-life: 1–2 hours for hydrocortisone (active component), prolonged in liver disease or with concurrent CYP3A4 inhibitors.
Ipramatropium: partially metabolized by hydrolysis to inactive metabolites; Albuterol: primarily metabolized by sulfate conjugation via SULT1A3 and to a lesser extent by CYP450 enzymes (CYP3A4, CYP2D6) to 4'-O-sulfate.
Topically applied; systemic absorption is minimal but can be increased with use on large areas, occlusive dressings, or damaged skin. Absorbed portion is metabolized primarily in the liver via hepatic microsomal enzymes (CYP3A4) and excreted by the kidneys.
Ipratropium is primarily excreted renally as unchanged drug (approximately 50%) and metabolites (approximately 30%); fecal excretion accounts for about 10%. Albuterol undergoes hepatic metabolism to an inactive sulfate conjugate, with approximately 70-80% of a dose excreted renally as unchanged drug and metabolite; fecal excretion is minimal (<10%).
Primarily hepatic metabolism (approximately 95%) followed by renal excretion of inactive metabolites (<5% unchanged). Biliary/fecal excretion is negligible.
Ipratropium: approximately 0-9% bound to plasma proteins (predominantly albumin). Albuterol: approximately 10% bound to plasma proteins.
Hydrocortisone is approximately 90–95% bound to corticosteroid-binding globulin (CBG, transcortin) and albumin.
Ipratropium: Vd approximately 2-4 L/kg (467 L for a 70 kg adult), indicating extensive tissue distribution. Albuterol: Vd approximately 1.5-2 L/kg (105-140 L for a 70 kg adult), consistent with moderate tissue distribution.
Apparent volume of distribution (Vd) is approximately 0.4–0.6 L/kg, indicating moderate tissue distribution and limited penetration into CNS.
Inhalation: Ipratropium absolute bioavailability of approximately 7-25% (due to pulmonary deposition and swallowed fraction). Albuterol inhaled bioavailability of approximately 10-20%. Oral bioavailability (swallowed) is low: ipratropium about 2-3%, albuterol about 30-50% but first-pass metabolism reduces systemic exposure.
Topical: Bioavailability is negligible (<1%) through intact skin; may increase (up to 30%) with damaged skin or occlusive dressings. Rectal: Bioavailability is approximately 10–20% via mucosal absorption, with first-pass metabolism reducing systemic exposure.
No dose adjustment required for mild-to-moderate renal impairment (Cr Cl >30 m L/min). Caution in severe impairment (Cr Cl <30 m L/min) or dialysis; use reduced frequency or alternative therapy due to potential for systemic accumulation.
No adjustment required for topical use; systemic absorption minimal.
No specific Child-Pugh based guidelines; caution in severe hepatic impairment (Child-Pugh class C) due to reduced clearance of albuterol, consider dose reduction or extended interval.
No adjustment required for topical use; hepatic metabolism negligible.
Not recommended for children <6 years. For ≥6 years: 2 inhalations 4 times daily as needed, up to 12 inhalations/day.
Children ≥2 years: Apply a thin film to affected area 2-3 times daily. Use lowest potency preparation; avoid prolonged use.
No specific dose adjustment; monitor for anticholinergic effects (e.g., dry mouth, urinary retention) and beta-adrenergic effects (e.g., tachycardia, tremor). Ensure proper inhaler technique; consider spacer use.
Use lowest effective dose; monitor for skin atrophy and systemic effects due to thinner skin and increased percutaneous absorption.
None
None
Paradoxical bronchospasm,Immediate hypersensitivity reactions,Deterioration in renal function (ipratropium eliminated renally),Cardiovascular effects: tachycardia, arrhythmias, hypertension (albuterol),Hypokalemia (albuterol),Increased intraocular pressure with nebulized ipratropium in glaucoma patients,Urinary retention in patients with prostatic hyperplasia or bladder neck obstruction
Systemic absorption may cause reversible HPA axis suppression,Cushing's syndrome, hyperglycemia, and glucosuria with prolonged use,Local adverse reactions: atrophy, striae, telangiectasias, acneiform eruptions, perioral dermatitis,May mask signs of infection,Use with caution in pediatric patients due to increased susceptibility to HPA axis suppression,Avoid use on face, intertriginous areas, and under occlusive dressings unless directed by physician
Hypersensitivity to ipratropium, albuterol, or any component of the formulation,Hypersensitivity to atropine or its derivatives
Hypersensitivity to any component of the formulation,Untreated bacterial, viral, fungal, or parasitic skin infections,Viral skin infections (e.g., herpes simplex, varicella) at treatment site,Perioral dermatitis,Rosacea
No specific food interactions are clinically significant. Avoid excessive caffeine intake (coffee, tea, cola, chocolate) as it may increase the risk of stimulant side effects (tremor, palpitations). Maintain adequate hydration to help manage possible dry mouth from ipratropium.
No known food interactions with topical ALA-CORT.
Pregnancy Category C. No adequate well-controlled studies in pregnant women. In animal studies, albuterol sulfate showed teratogenicity (cleft palate) at high doses; ipratropium bromide showed no teratogenic effects. Risk cannot be ruled out; use only if potential benefit justifies potential risk to fetus. First trimester: potential risk based on animal data. Second/third trimesters: albuterol may inhibit uterine contractions and cause maternal tachycardia, which may affect fetal heart rate; avoid near term due to possible neonatal hypoglycemia and hypokalemia.
FDA Pregnancy Category C. First trimester: No adequate human studies; animal studies show increased risk of cleft palate. Second/third trimester: Risk of intrauterine growth restriction, adrenal suppression in fetus. Avoid prolonged use.
Unknown if albuterol or ipratropium are excreted in human milk. M/P ratio not established. Caution advised; consider developmental and health benefits of breastfeeding along with mother's clinical need and potential adverse effects on nursing infant.
Provides small amounts in breast milk; M/P ratio unknown. At maternal doses up to 80 mg/day, no adverse effects reported in infants. Consider risk-benefit with high doses or prolonged therapy.
No specific dosing adjustment recommended for Combivent during pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, renal clearance) may affect albuterol; monitor clinical response and adjust dosing frequency if needed. Ipratropium has minimal systemic absorption; no adjustment anticipated.
Pregnancy-induced pharmacokinetic changes (increased clearance, volume of distribution) may require increased dosing, but clinical response should guide adjustment. Avoid high doses and prolonged use.
Combivent is a fixed-dose combination of ipratropium bromide (anticholinergic) and albuterol sulfate (beta-2 agonist) for COPD exacerbations. It should be used with caution in patients with narrow-angle glaucoma, bladder neck obstruction, or prostatic hypertrophy. Shake well before use. Rinse mouth after inhalation to prevent oral candidiasis and dysphonia. Monitor for paradoxical bronchospasm, hypokalemia, and cardiovascular effects (tachycardia, hypertension). Not indicated for acute episodes of asthma or as rescue monotherapy; consider separate short-acting beta-agonist for acute symptoms.
ALA-CORT (hydrocortisone acetate 2.5% and pramoxine HCl 1%) is a topical corticosteroid with anesthetic. Use for short-term relief of pruritus and inflammation in corticosteroid-responsive dermatoses. Avoid prolonged use on intertriginous or occluded areas. Limit to <2 weeks continuous use in adults to avoid skin atrophy. Not recommended for children <2 years.
Use exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Shake the inhaler well before each use (at least 10-15 seconds).,Prime the inhaler by spraying 4 test sprays into the air (away from face) before first use or if not used for more than 3 days.,Rinse your mouth with water after each use to reduce the risk of thrush (oral fungal infection) and hoarseness.,Seek immediate medical attention if you experience sudden worsening of breathing, chest pain, or signs of allergic reaction (rash, hives, swelling).,Inform your doctor if you have glaucoma, difficulty urinating, enlarged prostate, heart problems, or seizures.,Do not use with other inhaled medicines unless instructed by your doctor.,Keep inhaler clean; wipe mouthpiece with a dry cloth weekly.
Apply a thin layer to affected area no more than 3-4 times daily.,Do not cover with bandages or plastic unless directed by doctor.,Avoid contact with eyes, mouth, or broken skin.,Discontinue and notify doctor if infection, irritation, or no improvement after 7 days.,Do not use for diaper dermatitis or under diapers/occlusive dressings.,Keep out of reach of children.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about COMBIVENT vs ALA-CORT, answered by our medical review team.
COMBIVENT is a Bronchodilator Combination (Anticholinergic + Beta-2 Agonist) that works by Combivent is a fixed-dose combination of ipratropium bromide, an anticholinergic agent that inhibits muscarinic receptors in bronchial smooth muscle leading to bronchodilation, and albuterol sulfate, a beta-2 adrenergic agonist that stimulates adenyl cyclase, increasing cyclic AMP, resulting in bronchodilation.. ALA-CORT is a Topical Corticosteroid that works by Topical corticosteroid that induces phospholipase A2 inhibitory proteins, collectively called lipocortins, which inhibit the release of arachidonic acid, thereby reducing prostaglandin and leukotriene synthesis, and exerting anti-inflammatory, antipruritic, and vasoconstrictive effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between COMBIVENT and ALA-CORT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of COMBIVENT is: 2 inhalations (ipratropium 18 mcg and albuterol 103 mcg per actuation) via oral inhalation 4 times daily; maximum 12 inhalations in 24 hours.. The standard adult dose of ALA-CORT is: Topical: Apply a thin film to affected area 3-4 times daily. Dosage strength: 0.5% cream or ointment.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between COMBIVENT and ALA-CORT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. COMBIVENT is classified as Category C. Pregnancy Category C. No adequate well-controlled studies in pregnant women. In animal studies, albuterol sulfate showed teratogenicity (cleft palate) at high doses; ipratropium br. ALA-CORT is classified as Category C. FDA Pregnancy Category C. First trimester: No adequate human studies; animal studies show increased risk of cleft palate. Second/third trimester: Risk of intrauterine growth restri. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.